The phosphorylated analogue of DSIP enhances slow wave sleep and paradoxical sleep in unrestrained rats.
Kimura. M M; Inoué. S S
Key Findings
- P‑DSIP (0.5 nmol) raised slow‑wave (deep) sleep by ~22% and paradoxical (REM) sleep by ~81% in rats.
- The sleep boost came mainly from more sleep episodes, not longer episodes.
- Only the 0.5 nmol dose worked; lower or higher doses (0.025‑25 nmol) had no effect, and P‑DSIP was ~5× more potent than regular DSIP.
Practical Outcomes
- Because the peptide was infused directly into the brain of rats, the results aren’t ready for human use. It hints that a phosphorylated DSIP could be a stronger sleep aid, but we need safer delivery methods and human trials before any dosage or protocol can be recommended for biohackers.
Summary
A study in rats found that a modified version of the sleep‑inducing peptide (called P‑DSIP) boosted deep sleep and REM sleep when it was continuously delivered straight into the brain. The effect only showed up at one specific dose and was about five times stronger than the regular peptide.
Abstract
Continued 10-h nocturnal intracerebroventricular infusion of 0.5 nmol P-DSIP, the phosphorylated analogue of delta-sleep-inducing peptide (DSIP), significantly increased slow wave sleep (22%) and paradoxical sleep (81%) in unrestrained rats. The increase in the amount of sleep was largely due to an increase in the number of sleep episodes. Larger and smaller doses were ineffective in doses ranging from 0.025 to 25 nmol. The sleep-promoting potency of P-DSIP was 5 times greater than that of DSIP compared by the same assay.
Study Information
pubmed
1989
10.1007/bf00443409